Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443106 | 1.00 | PRKCI (0.45) | PRKCIAXLAURKBIKBKBCHUK | |
| SCHEMBL13386910 | 0.88 | PRKCI (0.42) | PRKCIAXLAURKBIKBKBCHUK | |
| SCHEMBL5533434 | 0.81 | PRKCI (0.41) | PRKCIAXLAURKBIKBKBCHUK | |
| SCHEMBL1564823 | 0.79 | PRKCI (0.43) | PRKCIAXLJAK2JAK3ROCK1 | |
| SCHEMBL18356291 | 0.77 | PIK3CD (0.40) | JAK2ROCK1RETCSNK1A1PRKCQ | |
| SCHEMBL30699163 | 0.77 | AXL (0.46) | AXLMAP4K4PRKACACDK9CDK5 | |
| SCHEMBL1895792 | 0.77 | AXL (0.46) | AXLMAP4K4PRKACACDK9CDK5 | |
| SCHEMBL21428757 | 0.76 | IKBKB (0.39) | AURKBIKBKBCHUKROCK1CCNK | |
| SCHEMBL21062801 | 0.75 | MAPK1 (0.34) | DYRK1A | |
| SCHEMBL16684601 | 0.75 | CCR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | PRKCI 226/4885AXL 626/4885AURKB 11/4885 |
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | PRKCI 930/4885AXL 92/4885AURKB 842/4885 |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | PRKCI 210/4885AXL 1509/4885AURKB 3/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | PRKCI 1049/4885AXL 1441/4885AURKB 568/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | PRKCI 2298/4885AXL 2575/4885AURKB 226/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | PRKCI 210/4885AXL 1509/4885AURKB 3/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | PRKCI 45/4885AXL 628/4885AURKB 528/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | PRKCI 17/4885AXL 699/4885AURKB 933/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | PRKCI 224/4885AXL 641/4885AURKB 11/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | PRKCI 1002/4885AXL 1683/4885AURKB 53/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | PRKCI 210/4885AXL 1509/4885AURKB 3/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | PRKCI 174/4885AXL 322/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.